Dow Up0.35% Nasdaq Down0.02%

Del Mar Pharmaceuticals Inc. (DMPI)

-Other OTC
0.73 Down 0.00(0.04%) 3:59PM EDT
ProfileGet Profile for:
Del Mar Pharmaceuticals Inc.
999 West Broadway
Suite 720
Vancouver, BC V5Z 1K5
Canada - Map
Phone: 604-629-5989

Index Membership:N/A
Full Time Employees:4

Business Summary 

DelMar Pharmaceuticals, Inc., a development stage company, focuses on the discovery and development of medicines with the potential to treat cancer patients who have failed modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity of VAL-083 in patients with glioblastoma multiforme, a form of brain cancer. DelMar Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Del Mar Pharmaceuticals Inc.

Key Executives 
Mr. Jeffrey A. Bacha B.Sc., M.B.A., 46
Co-Founder, Chairman, Chief Exec. Officer, Pres and Member of Steering Committee
Dr. Dennis M. Brown B.Sc., M.A., Ph.D., 65
Co-Founder, Chief Scientific Officer, Director and Member of Steering Committee
Dr. William J. Garner M.D., MPH, 48
Co-Founder and Director
Mr. Scott Praill , 47
Chief Financial Officer and Principal Accounting Officer
Dr. Victor Levin M.D.,
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders